Ferrimagnetic susceptibility contrast agents.
Contrast agents based on superparamagnetic particles have been in clinical development for more than 5 years, and the complexity of their effects is still not elucidated. The relaxivities are frequently used to give an idea of their efficacy, but these parameters can only be used if they are concentration independent. For large superparamagnetic systems, the evolution of the transverse magnetization is biexponential, after an initial loss of magnetization. Both these characteristics of large superparamagnetic systems should lead to prudence in using the relaxivities as indicators of contrast medium efficacy. Susceptibility induced artefacts have been associated with the use of superparamagnetic contrast agents since the first imaging evaluation took place. The range of concentrations where good contrast effect was achieved without inducing artefacts, as well as blurring and metal artefacts were evaluated. The influence of motion on the induction of artefacts was studied, and compared to the artefacts induced by a paramagnetic agent subject to motion. With a suitable concentration of a negative contrast agent, a signal void could be achieved in the region prone to motion, and no artefacts were induced. If the concentration was too high, a displacement of the region close to the contrast agent was observed. The artefacts occurred in a volume surrounding the contrast agent, i.e., also outside the imaging plane. In comparison a positive, paramagnetic contrast agent induced heavy artefacts in the phase encoding direction, appearing as both high intensity regions and black holes, in a mosaic pattern. Clinical trials of the oral contrast agent OMP for abdominal MR imaging showed this agent to be safe and efficacious. OMP increased the diagnostic efficacy of abdominal MR imaging in 2 of 3 cases examined, with a significant decrease in motion artefacts. Susceptibility contrast agents may also be of use in the evaluation of small lesions in the liver. Particulate material injected i.v. will be targeted to the liver and spleen by way of the mononuclear phagocyte system (MPS). Small particles, without specific receptor affinities were targeted to the hepatocytes and the MPS. The distribution correlated with a high efficiency as a contrast agent, whereas no correlation to in vitro relaxation rates and relaxivities could be found. Superparamagnetic particles have important possibilities as contrast agents. The identification of in vitro properties of these agents may help the comparison of various agents before in vivo imaging.
Department of Diagnostic Radiology, Uppsala University, Sweden.
T
T
Bach-Gansmo
D000818:Animals; D016477:Artifacts; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D003911:Dextrans; D004064:Digestive System / Q000473:pathology; D004578:Electron Spin Resonance Spectroscopy; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000737:chemistry; D052203:Ferrosoferric Oxide; D006801:Humans; D007089:Image Enhancement; D066298:In Vitro Techniques; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000737:chemistry; D008099:Liver / Q000473:pathology; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D058185:Magnetite Nanoparticles; D008297:Male; D008863:Microspheres; D008961:Models, Structural; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000737:chemistry; D010316:Particle Size; D011817:Rabbits; D012449:Safety
D003287:Contrast Media; D003911:Dextrans; D005290:Ferric Compounds; D058185:Magnetite Nanoparticles; D010087:Oxides; C069727:Sonazoid; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide